国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (7): 499-502.doi: 10.3760/cma.j.issn.1673422X.2016.07.005

• 论著 • 上一篇    下一篇

NOD2在肝癌中的表达及诊断价值

张晶鑫, 乔丽丽, 梁宁, 谢健, 罗辉, 邓国栋, 张建东   

  1. 潍坊医学院研究生院
  • 出版日期:2016-07-08 发布日期:2016-06-03
  • 基金资助:

    山东省自然科学基金（ZR2012HM095）

The expression and the diagnostic value of NOD2 in hepatocellular carcinoma

ZHANG  Jing-Xin, QIAO  Li-Li, LIANG  Ning, XIE  Jian, LUO  Hui, DENG  Guo-Dong, ZHANG  Jian-Dong   

  1. Graduate College of Weifang Medical University, Weifang 261061, China
  • Online:2016-07-08 Published:2016-06-03
  • Supported by:

    Natural Science Foundation of Shandong Province of China（ZR2012HM095）

PDF

1112

摘要： 目的探索核苷酸结合寡聚化结构域蛋白2（NOD2）在肝癌患者血清中的表达，分析NOD2在肝癌发生发展中的作用和临床诊断价值。方法选取2013年3月1日至2014年12月31日住院的肝癌患者66例和健康对照61例，采用酶联免疫吸附测定法(ELISA法)检测其血清中NOD2的表达情况。应用SPSS 16.0软件对数据进行统计学分析。结果肝癌患者血清中NOD2的中位浓度为171 pg/ml，显著高于对照组（95 pg/ml），差异有统计学意义（Z=-5.00,P=0.00）。NOD2浓度与肝癌患者的临床分期明显相关（H=56.26,P=0.00）。Ⅲ、Ⅳ期患者血清NOD2中位浓度为220 pg/ml，明显高于Ⅰ、Ⅱ期患者（106 pg/ml， χ2=31.24,P=0.00)和对照组（95 pg/ml， χ2=47.23,P=0.00）。Ⅰ、Ⅱ期患者血清NOD2中位浓度和对照组血清之间差异无统计学意义（χ2=0.36,P=0.83）。用ROC曲线分析得到了预测Ⅲ、Ⅳ期肝癌的最佳NOD2诊断临界值为148.78 pg/ml，对应的敏感性为89.1%，特异性为77.0%。相关性分析显示NOD2与甲胎蛋白（AFP）之间无明显相关（r=0.44，P=0.14）。生存曲线分析显示血清中NOD2浓度≥200 pg/ml的肝癌患者的生存时间明显少于血清中NOD2浓度＜200 pg/ml的肝癌患者(χ2=15.32，P<0.05)。结论NOD2在肝癌患者，尤其是在中晚期患者血清中呈高表达，可能与肝癌的发生发展有关，并且具有一定的诊断价值。

关键词: 肝肿瘤, 诊断,  , 甲胎蛋白类,  , 核苷酸结合寡聚化结构域蛋白2

Abstract: ObjectiveTo investigate the expression of nucleotidebinding oligomerization domain protein 2 (NOD2) in serum of patients with hepatocellular carcinoma (HCC), and to analyse the roles of NOD2 in HCC development and its clinical diagnostic value. MethodsThis study including 66 patients with HCC in the hospital from March 1, 2013 to December 31, 2014 and 61 healthy controls. Serum NOD2 levels were determined by enzymelinked immunosorbent assay (ELISA). Analysis of significance was performed with rank sum test using SPSS statistical 16.0 software. ResultsSerum levels of NOD2 in HCC patients were 171 pg/ml, significantly higher than that of healthy controls(95 pg/ml, Z=-5.00, P=0.00), and the serum NOD2 levels were correlated with clinical stage of HCC （H=56.26, P=0.00）. Compared with the serum NOD2 levels in stage Ⅰ, Ⅱ patients （106 pg/ml） and healthy controls (95 pg/ml), the serum NOD2 level in stage Ⅲ and Ⅳ (220 pg/ml) were significantly increased （χ2=31.24, P=0.00; χ2=47.23, P=0.00）, but the expression of NOD2 in stage Ⅰ and Ⅱ were nearly equal to that of the healthy controls （χ2=0.36, P=0.83）. The ROC analysis revealed that the best diagnostic cutoffpoint of serum NOD2 levels for predicting the Ⅲ and Ⅳ stages of HCC was 148.78 pg/ml, meanwhile corresponding sensitivity was 89.1% and specificity was 77.0%. Additionally, correlation analysis demonstrated that there was no significant correlation between NOD2 and alphafetal protein (r=0.44，P=0.14). Survival curves obtained that the survival time of HCC patients with NOD2 serum concentrations ≥ 200 pg/ml was significantly less than that ＜ 200 pg/ml (χ2=15.32, P<0.05). ConclusionNOD2 is highly expressed in the serum of HCC patients, especially in advanced patients, which is possibly involved in the development of HCC and has the potential to become an effective marker used for HCC diagnosis.

Key words: Liver neoplasms, Diagnosis, Alpha fetoproteins, Nucleotidebinding oligomerization domain protein 2